Key end points were ( @ ) percentage of responders at @ years ( ie , could consume @ g of peanut powder or a @-fold increase from baseline ) , ( @ ) percentage reaching desensitization at @ years , ( @ ) percentage attaining sustained unresponsiveness after @ years , ( @ ) immunologic end points , and ( @ ) assessment of safety parameters .